Physician profile
Marina E Goldis
NPI 1457601460
$8,611.31
in general payments reported to CMS, 2019-2025
43 companies · $597 in 2025
The $597 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $1,039 · 2021: $1,589 · 2022: $1,529 · 2023: $1,446 · 2024: $945 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980 · Education: $8.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.89 |
| Education | $8.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.13 | 2019-2025 | |
| Mannkind Corporation | $820.38 | 2019-2024 | Afrezza |
| Amneal Pharmaceuticals LLC | $791.48 | 2021-2025 | Unithroid |
| Novo Nordisk INC | $604.24 | 2019-2025 | Wegovy, Sogroya, Norditropin |
| Arbor Pharmaceuticals, INC. | $466.10 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $452.13 | 2022-2025 | Triptodur, Triptodur |
| Xeris Pharmaceuticals, INC. | $374.49 | 2020-2025 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $346.39 | 2021-2023 | Tepezza |
| Dexcom, INC. | $337.85 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $328.75 | 2019-2025 | Tepezza, Evenity, Prolia |
| Ferring Pharmaceuticals INC. | $306.07 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $269.66 | 2024-2025 | Skytrofa |
| Regeneron Healthcare Solutions, INC. | $264.90 | 2021-2023 | Evkeeza |
| Ipsen Biopharmaceuticals, INC | $261.78 | 2019-2023 | Somatuline Depot |
| Ibsa Pharma INC. | $239.48 | 2019-2023 | Tirosint, Licart |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Goldis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.